40,310 Shares in Celgene Co. (CELG) Acquired by Centre Asset Management LLC

Centre Asset Management LLC purchased a new position in Celgene Co. (NASDAQ:CELG) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 40,310 shares of the biopharmaceutical company’s stock, valued at approximately $5,878,000.

Several other institutional investors also recently bought and sold shares of CELG. Thompson Davis & CO. Inc. lifted its position in Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares in the last quarter. Motco lifted its position in Celgene by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 159 shares in the last quarter. Balentine LLC lifted its position in Celgene by 83.5% in the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 481 shares in the last quarter. Acropolis Investment Management LLC bought a new position in Celgene in the 2nd quarter valued at approximately $144,000. Finally, Rational Advisors LLC bought a new position in Celgene in the 2nd quarter valued at approximately $156,000. Institutional investors own 80.16% of the company’s stock.

In other Celgene news, insider Terrie Curran sold 1,727 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.95% of the company’s stock.

Shares of Celgene Co. (NASDAQ CELG) opened at $109.41 on Friday. Celgene Co. has a 12 month low of $94.55 and a 12 month high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $86,140.36, a price-to-earnings ratio of 17.10, a price-to-earnings-growth ratio of 0.84 and a beta of 1.78.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the prior year, the business posted $1.58 EPS. Celgene’s revenue for the quarter was up 10.2% compared to the same quarter last year. equities analysts expect that Celgene Co. will post 6.68 earnings per share for the current fiscal year.

Several equities analysts recently issued reports on CELG shares. Vetr cut Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective on the stock. in a research report on Tuesday, August 29th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene in a research report on Monday, August 28th. Robert W. Baird reaffirmed a “buy” rating and issued a $162.00 price objective on shares of Celgene in a research report on Thursday, September 21st. Jefferies Group reaffirmed a “buy” rating and issued a $160.00 price objective on shares of Celgene in a research report on Friday, September 15th. Finally, Mizuho upped their price objective on Celgene from $134.00 to $158.00 and gave the company a “buy” rating in a research report on Friday, September 15th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $136.21.

COPYRIGHT VIOLATION NOTICE: “40,310 Shares in Celgene Co. (CELG) Acquired by Centre Asset Management LLC” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/12/17/40310-shares-in-celgene-co-celg-acquired-by-centre-asset-management-llc.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply